- Home
- OSBC vs GERN Comparison
OSBC vs GERN Comparison
Compare OSBC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSBC | GERN |
|---|---|---|
| Founded | 1981 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | OSBC | GERN |
|---|---|---|
| Price | $19.97 | $1.51 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $22.70 | $2.17 |
| AVG Volume (30 Days) | 377.9K | ★ 18.1M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.20 | $26.91 |
| Revenue Next Year | $3.66 | $43.75 |
| P/E Ratio | $12.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.28 | $1.04 |
| 52 Week High | $22.43 | $2.01 |
Technical Indicators
Market Signals| Indicator | OSBC | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 43.43 |
| Support Level | $19.20 | $1.41 |
| Resistance Level | $20.10 | $1.72 |
| Average True Range (ATR) | 0.56 | 0.09 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 23.58 | 10.81 |
Price Performance
Historical ComparisonAbout OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.